AC Immune (ACIU) Scheduled to Post Earnings on Friday

AC Immune (NASDAQ:ACIU) is scheduled to release its earnings data on Friday, April 26th.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million during the quarter, compared to analysts’ expectations of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Trading Down 0.4 %

ACIU stock opened at $2.37 on Thursday. The company’s 50 day moving average is $3.12 and its two-hundred day moving average is $3.34. AC Immune has a twelve month low of $1.78 and a twelve month high of $5.14. The stock has a market cap of $234.39 million, a P/E ratio of -3.34 and a beta of 1.00.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a research note on Friday, March 15th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.